Download PDF
Drug Res (Stuttg) 2020; 70(10): 478-483
DOI: 10.1055/a-1223-1734
Original Article

Silibinin Inhibit Cell Migration through Downregulation of RAC1 Gene Expression in Highly Metastatic Breast Cancer Cell Line

Hamed Esmaeil Lashgarian
1   Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
,
Vahid Adamii
1   Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
,
Vajihe Ghorbanzadeh
2   Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
,
Leila Chodari
3   Department of Physiology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran
4   Neurophysiology Research Center, Urmia University of Medical Sciences, Urmia, Iran
,
Fayze Kamali
1   Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
,
Soheila Akbari
5   Department of Obstetrics and Gynecology, Lorestan University of Medical Sciences, Khorramabad, Iran
,
Hassan Dariushnejad
1   Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
2   Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
› Author Affiliations Funding This study was funded by Deputy of Research and Technology (grant No. 1208), Lorestan University of Medical Sciences, Khorramabad, Iran. The results presented in this work are based on data set of MSc thesis, recorded in Lorestan University of Medical Sciences.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Background Triple negative breast cancer is the most invasive breast cancer subtype and possesses poor prognosis and survival. Rho GTPase famil, especially Rac1 participates in a number of signaling events in cells with crucial roles in malignancy, migration and invasion of tumor cells. Silibinin, a flavonoid antioxidant from milk thistle has attracted attention in the recent decades for chemoprevention and chemotherapy of tumor cells. In this study, the effect of silibinin on the migration capacity of MDA-MB-231 cells, a highly metastatic human breast cancer cell line was investigated by evaluation of Rac1 expression.

Method MTT wound healing and transwell assays were performed to evaluate the effects of silibinin on proliferation and migration of MDA-MB-231 cells. In addition, the influence of the silibinin on the expression of Rac1mRNAs was assessed by RT-PCR.

Results Results indicated significant dose-dependent inhibitory effect of silibinin on proliferation and migration of MDA-MB-231 cells. It significantly inhibited the expression of Rac1 mRNA.

Conclusion In conclusion, the results demonstrate that the silibinin can be used as an experimental therapeutic for the management of TNBC metastatic cancer.

Key words

silibinin - breast cancer - TNBC - Rac1 - metastasis


Publication History

Received: 18 June 2020

Accepted: 13 July 2020

Article published online:
13 August 2020

© 2020. Thieme. All rights reserved.

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Di Micco R, Santurro L, Gasparri ML, Zuber V, Fiacco E, Gazzetta G, et al. Rare sites of breast cancer metastasis: a review. Translational Cancer Research. 2019
    PubMed
  • 2 Razak NA, Abu N, Ho WY, Zamberi NR, Tan SW, Alitheen NB. et al. Cytotoxicity of eupatorin in MCF-7 and MDA-MB-231 human breast cancer cells via cell cycle arrest, anti-angiogenesis and induction of apoptosis. Scientific Reports 2019; 9
    PubMedGoogle Scholar
  • 3 Kopfstein L, Christofori G. Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cellular and Molecular Life Sciences CMLS 2006; 63: 449-468
    CrossrefPubMedGoogle Scholar
  • 4 Iden S, Collard JG. Crosstalk between small GTPases and polarity proteins in cell polarization. Nature Reviews Molecular Cell Biology 2008; 9: 846
    CrossrefPubMedGoogle Scholar
  • 5 Yang Z, Chen H, Shu M, Zhang Y, Xue L, Lin Y. DLC2 operates as a tumor suppressor gene in breast cancer via the RhoGTPase pathway. Oncology Letters 2019; 17: 2107-2116
    PubMedGoogle Scholar
  • 6 Xiao Y, Li Y, Tao H, Humphries B, Li A, Jiang Y. et al. Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway. Cancer Letters 2018; 433: 199-209
    CrossrefPubMedGoogle Scholar
  • 7 Karpel-Massler G, Westhoff M-A, Zhou S, Nonnenmacher L, Dwucet A, Kast RE. et al. Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells. Molecular Cancer Therapeutics 2013; 12: 1783-1795
    CrossrefPubMedGoogle Scholar
  • 8 Bosco E, Mulloy J, Zheng Y. Rac1 GTPase: a “Rac” of all trades. Cellular and Molecular Life Sciences 2009; 66: 370
    CrossrefPubMedGoogle Scholar
  • 9 Kiosses WB, Shattil SJ, Pampori N, Schwartz MA. Rac recruits high-affinity integrin αvβ3 to lamellipodia in endothelial cell migration. Nature Cell Biology 2001; 3: 316
    CrossrefPubMedGoogle Scholar
  • 10 Yamazaki D, Kurisu S, Takenawa T. Regulation of cancer cell motility through actin reorganization. Cancer Science 2005; 96: 379-386
    CrossrefPubMedGoogle Scholar
  • 11 Abotaleb M, Samuel SM, Varghese E, Varghese S, Kubatka P, Liskova A. et al. Flavonoids in cancer and apoptosis. Cancers 2019; 11: 28
    CrossrefPubMedGoogle Scholar
  • 12 Abbaszadeh H, Keikhaei B, Mottaghi S A review of molecular mechanisms involved in anticancer and antiangiogenic effects of natural polyphenolic compounds. Phytotherapy Research 2019; 33: 2002-2014
    PubMed
  • 13 Si L, Liu W, Hayashi T, Ji Y, Fu J, Nie Y. et al. Silibinin-induced apoptosis of breast cancer cells involves mitochondrial impairment. Archives of Biochemistry and Biophysics 2019; 671: 42-51
    CrossrefPubMedGoogle Scholar
  • 14 Yang Z, Pan Q, Zhang D, Chen J, Qiu Y, Chen X. et al. Silibinin restores the sensitivity of cisplatin and taxol in A2780-resistant cell and reduces drug-induced hepatotoxicity. Cancer Management and Research 2019; 11: 7111
    CrossrefPubMedGoogle Scholar
  • 15 Flaig TW, Gustafson DL, Su L-J, Zirrolli JA, Crighton F, Harrison GS. et al. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Investigational New Drugs 2007; 25: 139-146
    CrossrefPubMedGoogle Scholar
  • 16 Su Q, Peng M, Zhang Y, Xu W, Darko KO, Tao T. et al. Quercetin induces bladder cancer cells apoptosis by activation of AMPK signaling pathway. American Journal of Cancer Research 2016; 6: 498
    PubMedGoogle Scholar
  • 17 Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007; 109: 1721-1728
    CrossrefPubMedGoogle Scholar
  • 18 Wu K-j ZengJ, Zhu G-d ZhangL-l, Zhang D, Li L. et al. Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression. Acta Pharmacologica Sinica 2009; 30: 1162
    CrossrefPubMedGoogle Scholar
  • 19 Chang HR, Chen PN, Yang SF, Sun YS, Wu SW, Hung TW. et al. Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel. Molecular Carcinogenesis 2011; 50: 811-823
    CrossrefPubMedGoogle Scholar
  • 20 Nejati-Koshki K, Akbarzadeh A, Pourhasan-Moghaddam M, Abhari A, Dariushnejad H. Inhibition of leptin and leptin receptor gene expression by silibinin-curcumin combination. Asian Pacific Journal of Cancer Prevention 2013; 14: 6595-6599
    CrossrefPubMedGoogle Scholar
  • 21 Tiwari P, Mishra K. Silibinin in cancer therapy: A promising prospect. Cancer Res Front 2015; 1: 303-318
    CrossrefPubMedGoogle Scholar
  • 22 Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer and Metastasis Reviews 2010; 29: 447-463
    CrossrefPubMedGoogle Scholar
  • 23 Byun HJ, Darvin P, Kang DY, Sp N, Joung YH, Park JH. et al. Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells. Oncology Reports 2017; 37: 3270-3278
    CrossrefPubMedGoogle Scholar
  • 24 Chen J, Thompson LU. Lignans and tamoxifen, alone or in combination, reduce human breast cancer cell adhesion, invasion and migration in vitro. Breast Cancer Research and Treatment 2003; 80: 163-170
    CrossrefPubMedGoogle Scholar
  • 25 De P, Aske JC, Dey N. RAC1 Takes the Lead in Solid Tumors. Cells 2019; 8: 382
    CrossrefPubMedGoogle Scholar